BidaskClub upgraded shares of AMAG Pharmaceuticals (NASDAQ:AMAG) from a buy rating to a strong-buy rating in a research report sent to investors on Tuesday.
AMAG has been the subject of a number of other research reports. Jefferies Group lowered AMAG Pharmaceuticals from a buy rating to a hold rating and lowered their target price for the stock from $21.00 to $20.00 in a report on Monday, March 5th. Leerink Swann started coverage on AMAG Pharmaceuticals in a report on Monday. They set a market perform rating and a $24.65 target price for the company. Cantor Fitzgerald restated a hold rating and set a $17.00 target price on shares of AMAG Pharmaceuticals in a report on Wednesday, February 14th. ValuEngine upgraded AMAG Pharmaceuticals from a sell rating to a hold rating in a report on Wednesday, February 28th. Finally, Piper Jaffray Companies restated a hold rating and set a $20.00 target price on shares of AMAG Pharmaceuticals in a report on Thursday, March 1st. Ten investment analysts have rated the stock with a hold rating, three have issued a buy rating and one has issued a strong buy rating to the company. AMAG Pharmaceuticals currently has an average rating of Hold and an average target price of $23.97.
AMAG Pharmaceuticals opened at $23.10 on Tuesday, MarketBeat Ratings reports. The company has a quick ratio of 1.48, a current ratio of 1.57 and a debt-to-equity ratio of 0.97. The firm has a market cap of $810.11 million, a price-to-earnings ratio of -4.05 and a beta of 0.10. AMAG Pharmaceuticals has a twelve month low of $11.93 and a twelve month high of $24.92.
AMAG Pharmaceuticals (NASDAQ:AMAG) last posted its earnings results on Thursday, May 3rd. The specialty pharmaceutical company reported ($1.59) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.49) by ($1.10). The company had revenue of $146.40 million for the quarter, compared to analysts’ expectations of $149.13 million. AMAG Pharmaceuticals had a negative return on equity of 1.15% and a negative net margin of 35.17%. The firm’s quarterly revenue was up 4.9% on a year-over-year basis. During the same quarter in the prior year, the company earned ($1.06) EPS. analysts anticipate that AMAG Pharmaceuticals will post -3.02 earnings per share for the current fiscal year.
Several institutional investors and hedge funds have recently modified their holdings of the company. New York State Teachers Retirement System lifted its holdings in shares of AMAG Pharmaceuticals by 11.9% during the 1st quarter. New York State Teachers Retirement System now owns 38,625 shares of the specialty pharmaceutical company’s stock valued at $778,000 after purchasing an additional 4,100 shares during the last quarter. Northern Trust Corp lifted its holdings in shares of AMAG Pharmaceuticals by 1.0% during the 1st quarter. Northern Trust Corp now owns 458,445 shares of the specialty pharmaceutical company’s stock valued at $9,237,000 after purchasing an additional 4,468 shares during the last quarter. Two Sigma Investments LP lifted its holdings in shares of AMAG Pharmaceuticals by 14.8% during the 4th quarter. Two Sigma Investments LP now owns 35,287 shares of the specialty pharmaceutical company’s stock valued at $468,000 after purchasing an additional 4,542 shares during the last quarter. Geode Capital Management LLC lifted its holdings in shares of AMAG Pharmaceuticals by 1.5% during the 4th quarter. Geode Capital Management LLC now owns 377,479 shares of the specialty pharmaceutical company’s stock valued at $5,001,000 after purchasing an additional 5,452 shares during the last quarter. Finally, Swiss National Bank lifted its holdings in shares of AMAG Pharmaceuticals by 13.0% during the 1st quarter. Swiss National Bank now owns 63,457 shares of the specialty pharmaceutical company’s stock valued at $1,279,000 after purchasing an additional 7,300 shares during the last quarter.
About AMAG Pharmaceuticals
AMAG Pharmaceuticals, Inc, a biopharmaceutical company, manufactures, develops, and commercializes therapeutics for maternal and women's health, anemia management, and cancer supportive care in the United States. It markets Makena, a hydroxyprogesterone caproate injection to reduce the risk of preterm birth in women pregnant with a single baby who have a history of singleton spontaneous preterm birth; Feraheme (ferumoxytol), an intravenous iron replacement therapeutic agent for the treatment of iron deficiency anemia in adult patients who have intolerance to oral iron or have had unsatisfactory response to oral iron, as well as patients who have chronic kidney disease; Intrarosa(prasterone) vaginal insert steroid for the treatment of dyspareunia due to menopause; and MuGard Mucoadhesive Oral Wound Rinse for the management of oral mucocitis/stomatiits and various types of oral wounds.
Receive News & Ratings for AMAG Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AMAG Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.